GIRISHKUMAR SHAH: Open Payments
NPI 1538210109 · HAMMOND, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,222 in 47 payments from 12 companies in 2025. Trend: 2023 $855 · 2024 $1,454 · 2025 $1,222
Food & beverage: $1,222
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $447 |
| Janssen Pharmaceuticals, Inc | 8 | $198 |
| Alkermes, Inc. | 3 | $168 |
| Otsuka America Pharmaceutical, Inc. | 3 | $83 |
| ABBVIE INC. | 5 | $78 |
| Neurocrine BioSciences, Inc. | 3 | $59 |
| Indivior Inc. | 3 | $56 |
| Lundbeck LLC | 3 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Axsome Therapeutics, Inc. | 1 | $18 |
Products named: CAPLYTA, LYBALVI, INVEGA SUSTENNA, REXULTI, VRAYLAR, SPRAVATO, INGREZZA, SUBLOCADE.
Industry payments across LA — which companies pay providers there.
